

Luigi Nocera

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8786661/publications.pdf>

Version: 2024-02-01

114
papers

931
citations

623188

14
h-index

552369

26
g-index

134
all docs

134
docs citations

134
times ranked

939
citing authors

#	ARTICLE	IF	CITATIONS
1	Development and Internal Validation of a Novel Model to Identify the Candidates for Extended Pelvic Lymph Node Dissection in Prostate Cancer. <i>European Urology</i> , 2017, 72, 632-640.	0.9	165
2	Robot-assisted Radical Prostatectomy with the Novel Hugo Robotic System: Initial Experience and Optimal Surgical Set-up at a Tertiary Referral Robotic Center. <i>European Urology</i> , 2022, 82, 233-237.	0.9	66
3	Surgical Safety of Radical Cystectomy and Pelvic Lymph Node Dissection Following Neoadjuvant Pembrolizumab in Patients with Bladder Cancer: Prospective Assessment of Perioperative Outcomes from the PURE-01 Trial. <i>European Urology</i> , 2020, 77, 576-580.	0.9	55
4	Efficacy of Local Treatment in Prostate Cancer Patients with Clinically Pelvic Lymph Node-positive Disease at Initial Diagnosis. <i>European Urology</i> , 2018, 73, 452-461.	0.9	46
5	Incidence and Survival Rates of Contemporary Patients with Invasive Upper Tract Urothelial Carcinoma. <i>European Urology Oncology</i> , 2021, 4, 792-801.	2.6	40
6	Clinical Outcomes and Adverse Events after First-Line Treatment in Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-Analysis. <i>Journal of Urology</i> , 2022, 207, 16-24.	0.2	31
7	Overall Survival After Systemic Treatment in High-volume Versus Low-volume Metastatic Hormone-sensitive Prostate Cancer: Systematic Review and Network Meta-analysis. <i>European Urology Focus</i> , 2022, 8, 399-408.	1.6	29
8	Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 139-148.	2.0	28
9	Functional outcomes of clinically high-risk prostate cancer patients treated with robot-assisted radical prostatectomy: a multi-institutional analysis. <i>Prostate Cancer and Prostatic Diseases</i> , 2017, 20, 395-400.	2.0	27
10	Bladder Cancer: A Comparison Between Non-urothelial Variant Histology and Urothelial Carcinoma Across All Stages and Treatment Modalities. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 60-68.e1.	0.9	27
11	Upper Urinary Tract Tumors: Variant Histology Versus Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 117-124.	0.9	22
12	Life expectancy in metastatic prostate cancer patients according to racial/ethnic groups. <i>International Journal of Urology</i> , 2021, 28, 862-869.	0.5	22
13	Immunotherapy versus chemotherapy as first-line treatment for advanced urothelial cancer: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2022, 104, 102360.	3.4	22
14	Tumor Size Predicts Muscle-invasive and Non-organ-confined Disease in Upper Tract Urothelial Carcinoma at Radical Nephroureterectomy. <i>European Urology Focus</i> , 2022, 8, 498-505.	1.6	17
15	Tumor Stage and Substage Predict Cancer-specific Mortality After Nephrectomy for Nonmetastatic Renal Cancer: Histological Subtype-specific Validation. <i>European Urology Focus</i> , 2022, 8, 182-190.	1.6	15
16	Incidence rates and contemporary trends in primary urethral cancer. <i>Cancer Causes and Control</i> , 2021, 32, 627-634.	0.8	15
17	Increasing rates of NCCN high and very high-risk prostate cancer versus number of prostate biopsy cores. <i>Prostate</i> , 2021, 81, 874-881.	1.2	15
18	Rate and Extent of Pelvic Lymph Node Dissection in the US Prostate Cancer Patients Treated With Radical Prostatectomy. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e451-e467.	0.9	14

#	ARTICLE	IF	CITATIONS
19	The effect of lymph node dissection on cancer-specific survival in salvage radical prostatectomy patients. <i>Prostate</i> , 2021, 81, 339-346.	1.2	13
20	Differences between rural and urban prostate cancer patients. <i>World Journal of Urology</i> , 2021, 39, 2507-2514.	1.2	12
21	Racial/Ethnic Disparities in Tumor Characteristics and Treatments in Favorable and Unfavorable Intermediate Risk Prostate Cancer. <i>Journal of Urology</i> , 2021, 206, 69-79.	0.2	12
22	Predicting the risk of pT3a stage in cT1 clear cell renal cell carcinoma. <i>European Journal of Surgical Oncology</i> , 2021, 47, 1187-1190.	0.5	11
23	The Impact of Race and Age on Distribution of Metastases in Patients with Prostate Cancer. <i>Journal of Urology</i> , 2020, 204, 962-968.	0.2	11
24	Bladder cancer stage and mortality: urban vs. rural residency. <i>Cancer Causes and Control</i> , 2021, 32, 139-145.	0.8	10
25	Improving the stratification of intermediate risk prostate cancer. <i>Minerva Urology and Nephrology</i> , 2022, 74, .	1.3	10
26	Survival advantage of Asian metastatic prostate cancer patients treated with external beam radiotherapy over other races/ethnicities. <i>World Journal of Urology</i> , 2021, 39, 3781-3787.	1.2	9
27	Radical Cystectomy vs. Multimodality Treatment in T2N0M0 Bladder Cancer: A Population-based, Age-matched Analysis. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e264-e271.	0.9	9
28	The impact of race/ethnicity on upstaging and/or upgrading rates among intermediate risk prostate cancer patients treated with radical prostatectomy. <i>World Journal of Urology</i> , 2022, 40, 103-110.	1.2	9
29	Micropapillary Versus Urothelial Carcinoma of the Urinary Bladder: Stage at Presentation and Efficacy of Chemotherapy Across All Stages – A SEER-based Study. <i>European Urology Focus</i> , 2021, 7, 1332-1338.	1.6	8
30	Improving the Stratification of Patients With Intermediate-risk Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e120-e128.	0.9	8
31	Race/Ethnicity Determines Life Expectancy in Surgically Treated T1aN0M0 Renal Cell Carcinoma Patients. <i>European Urology Focus</i> , 2022, 8, 191-199.	1.6	8
32	Salvage Radical Prostatectomy: Baseline Prostate Cancer Characteristics and Survival Across SEER Registries. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e255-e263.	0.9	8
33	Regional differences in patient age and prostate cancer characteristics and rates of treatment modalities in favorable and unfavorable intermediate risk prostate cancer across United States SEER registries. <i>Cancer Epidemiology</i> , 2021, 74, 101994.	0.8	8
34	Comparison Between Urothelial and Non-Urothelial Urethral Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 629692.	1.3	8
35	Obesity is associated with adverse short-term perioperative outcomes in patients treated with open and robot-assisted radical cystectomy for bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 75.e17-75.e25.	0.8	7
36	Sex-Related Differences Include Stage, Histology, and Survival in Urethral Cancer Patients. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 135-143.	0.9	7

#	ARTICLE	IF	CITATIONS
37	Sex- and Age-Related Differences in the Distribution of Metastases in Patients With Upper Urinary Tract Urothelial Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 534-540.	2.3	7
38	Efficacy of local treatment in prostate cancer patients with clinically pelvic lymph node-positive disease at initial diagnosis. <i>European Urology Supplements</i> , 2017, 16, e1862-e1864.	0.1	6
39	External beam radiation therapy improves survival in low-volume metastatic prostate cancer patients: a North American population-based study. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 253-260.	2.0	6
40	Higher Cancer Mortality in Rural Upper Urinary Tract Urothelial Carcinoma Patients. <i>Urologia Internationalis</i> , 2021, 105, 624-630.	0.6	6
41	The effect of race/ethnicity on active treatment rates among septuagenarian or older low risk prostate cancer patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 785.e11-785.e17.	0.8	6
42	The role of nephrectomy in metastatic renal cell carcinoma in the immuno-oncology era. <i>BJU International</i> , 2021, 128, 438-439.	1.3	6
43	The effect of race on stage at presentation and survival in upper tract urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 788.e7-788.e13.	0.8	6
44	Comparison between 1973 and 2004/2016 WHO grading systems in patients with Ta urothelial carcinoma of urinary bladder. <i>Journal of Clinical Pathology</i> , 2021, , jclinpath-2021-207400.	1.0	5
45	Radical prostatectomy improves survival in selected metastatic prostate cancer patients: A North American population-based study. <i>International Journal of Urology</i> , 2021, 28, 834-839.	0.5	5
46	Comparison between 1973 and 2004/2016 World Health Organization grading in upper tract urothelial carcinoma treated with radical nephroureterectomy. <i>International Journal of Clinical Oncology</i> , 2021, 26, 1707-1713.	1.0	5
47	Contemporary analysis of the effect of marital status on survival in upper tract urothelial carcinoma patients treated with radical nephroureterectomy: A population-based study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 789.e9-789.e17.	0.8	5
48	The effect of primary urological cancers on survival in men with secondary prostate cancer. <i>Prostate</i> , 2021, 81, 1149-1158.	1.2	5
49	The effect of race/ethnicity on histological subtype distribution, stage at presentation and cancer specific survival in urethral cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 369.e9-369.e17.	0.8	4
50	A novel expressed prostatic secretion (EPS)-urine metabolomic signature for the diagnosis of clinically significant prostate cancer. <i>Cancer Biology and Medicine</i> , 2021, 18, 604-615.	1.4	4
51	Temporal trends, tumor characteristics and stage-specific survival in penile non-squamous cell carcinoma vs. squamous cell carcinoma. <i>Cancer Causes and Control</i> , 2022, 33, 25-35.	0.8	4
52	Comparison of Mexican-American vs Caucasian prostate cancer active surveillance candidates. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 74.e1-74.e7.	0.8	4
53	Stage and cancer-specific mortality differ within specific Asian ethnic groups for upper tract urothelial carcinoma: North American population-based study. <i>International Journal of Urology</i> , 2021, 28, 1247-1252.	0.5	3
54	Survival rates with external beam radiation therapy in newly diagnosed elderly metastatic prostate cancer patients. <i>Prostate</i> , 2022, 82, 78-85.	1.2	3

#	ARTICLE	IF	CITATIONS
55	Contemporary Trends and Efficacy of Pelvic Lymph Node Dissection at Radical Cystectomy for Urothelial and Variant Histology Carcinoma of the Urinary Bladder. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 195.e1-195.e8.	0.9	3
56	A Nomogram-Based Model to Predict Respiratory Dysfunction at 6 Months in Non-Critical COVID-19 Survivors. <i>Frontiers in Medicine</i> , 2022, 9, 781410.	1.2	3
57	Race/Ethnicity may be an Important Predictor of Life Expectancy in Localized Prostate Cancer Patients: Novel Analyses Using Social Security Administration Life Tables. <i>Journal of Racial and Ethnic Health Disparities</i> , 2023, 10, 708-717.	1.8	3
58	Median time to progression with TKI-based therapy after failure of immuno-oncology therapy in metastatic kidney cancer: A systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2021, 155, 245-255.	1.3	2
59	Response to the letter to the editor: "Don't throw the baby out with the bath water" by Horsley et al.. <i>Prostate</i> , 2022, 82, 399-400.	1.2	2
60	PD40-07 CLINICAL OUTCOMES AND ADVERSE EVENTS AFTER FIRST-LINE TREATMENT IN METASTATIC RENAL CELL CARCINOMA: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS. <i>Journal of Urology</i> , 2021, 206, .	0.2	1
61	MP50-14 THE IMPACT OF RACE/ETHNICITY ON UPSTAGING AND/OR UPGRADING RATES AMONG INTERMEDIATE RISK PROSTATE CANCER PATIENTS TREATED WITH RADICAL PROSTATECTOMY. <i>Journal of Urology</i> , 2021, 206, .	0.2	1
62	Efficacy of local treatment in patients with prostate cancer with clinically pelvic lymph node-positive disease at initial diagnosis.. <i>Journal of Clinical Oncology</i> , 2017, 35, 164-164.	0.8	1
63	PD51-10 SURVIVAL AFTER RADICAL PROSTATECTOMY IN PATIENTS WITH PSA PERSISTENCE: THE IMPACT OF COMPETING CAUSES OF MORTALITY. <i>Journal of Urology</i> , 2017, 197, .	0.2	0
64	PD43-11 LACK OF SUSTAINABLE RESPONSE TO THE 2012 UNITED STATES PREVENTIVE SERVICES TASK FORCE (USPSTF) RECOMMENDATION AGAINST PROSTATE CANCER (PCA) SCREENING. <i>Journal of Urology</i> , 2017, 197, .	0.2	0
65	Does the inclusion of non-index lesions at biopsy improve our ability to predict adverse pathologic outcomes at radical prostatectomy? Implications for targeted plus systematic biopsy schemes. <i>European Urology Supplements</i> , 2017, 16, e877-e878.	0.1	0
66	MP03-04 DOES THE INCLUSION OF NON-INDEX LESIONS AT BIOPSY IMPROVE OUR ABILITY TO PREDICT ADVERSE PATHOLOGIC OUTCOMES AT RADICAL PROSTATECTOMY? IMPLICATIONS FOR TARGETED PLUS SYSTEMATIC BIOPSY SCHEMES. <i>Journal of Urology</i> , 2017, 197, .	0.2	0
67	MP53-18 EFFICACY OF LOCAL TREATMENT IN PROSTATE CANCER PATIENTS WITH CLINICALLY PELVIC LYMPH NODE-POSITIVE DISEASE AT INITIAL DIAGNOSIS. <i>Journal of Urology</i> , 2017, 197, .	0.2	0
68	Impact of neoadjuvant pembrolizumab on intra and peri-operative complications after radical cystectomy: A comparison with both standard chemotherapy and no adjuvant treatment. <i>European Urology Supplements</i> , 2019, 18, e3239.	0.1	0
69	Is one targeted biopsy core of the index lesion sufficient to accurately detect clinically significant prostate cancer across all PI-RADS scores?. <i>European Urology Supplements</i> , 2019, 18, e1802-e1803.	0.1	0
70	Re: Hiten D. Patel, Farzana A. Faisal, Bruce J. Trock, et al. Effect of Pharmacologic Prophylaxis on Venous Thromboembolism After Radical Prostatectomy: The PREVENTER Randomized Clinical Trial. <i>Eur Urol</i> 2020;78:360-368. <i>European Urology</i> , 2021, 79, e33-e34.	0.9	0
71	Identifying the most informative cut-off of psa to define biochemical recurrence after radical prostatectomy: A stage-by-stage analysis. <i>European Urology</i> , 2021, 79, S1649.	0.9	0
72	Positive predictive value of mpMRI in men under active surveillance: Can the biopsy history influence radiological assessment?. <i>European Urology</i> , 2021, 79, S1286.	0.9	0

#	ARTICLE	IF	CITATIONS
73	The detection of a PI-RADS 4-5 lesion at multiparametric MRI before confirmatory biopsy. Is the strongest predictor of disease progression among men with low-risk prostate cancer included in an active surveillance prospective protocol. <i>European Urology</i> , 2021, 79, S1310.	0.9	0
74	Reply by Authors. <i>Journal of Urology</i> , 2021, 206, 79-79.	0.2	0
75	MP05-12â€¦SHOULD WE ROUTINELY RECOMMEND A CENTRAL REVIEW OF MAGNETIC RESONANCE IMAGING OF THE PROSTATE IN MEN WITH POSITIVE MP-MRI? IMPLICATION FOR TARGETED BIOPSIES. <i>Journal of Urology</i> , 2021, 206, .	0.2	0
76	MP62-20â€¦THE DETECTION OF A PI-RADS 4-5 LESION AT MULTIPARAMETRIC MRI BEFORE CONFIRMATORY BIOPSY IS THE STRONGEST PREDICTOR OF DISEASE PROGRESSION AMONG MEN WITH LOW-RISK PROSTATE CANCER INCLUDED IN AN ACTIVE SURVEILLANCE PROSPECTIVE PROTOCOL. <i>Journal of Urology</i> , 2021, 206, .	0.2	0
77	MP43-08â€¦INCREASING RATES OF NCCN HIGH AND VERY HIGH-RISK PROSTATE CANCER VS. NUMBER OF PROSTATE BIOPSY CORES. <i>Journal of Urology</i> , 2021, 206, .	0.2	0
78	MP43-12â€¦ASSESSING THE NEED FOR SYSTEMATIC BIOPSIES IN ADDITION TO TARGETED BIOPSIES ACCORDING TO THE VOLUME OF THE INDEX LESION DIAGNOSED AT MPMRI. RESULTS FROM A LARGE, MULTI-INSTITUTIONAL DATABASE. <i>Journal of Urology</i> , 2021, 206, .	0.2	0
79	PD57-10â€¦OPTIMIZING THE NUMBER OF SYSTEMATIC CORES DURING AN MRI TARGET BIOPSY: PRELIMINARY RESULTS FROM THE PROSPECTIVE, SINGLE CENTER SCOT TRIAL (NCT 04183699). <i>Journal of Urology</i> , 2021, 206, .	0.2	0
80	PD61-09â€¦FINAL RESULTS OF A PROSPECTIVE, RANDOMIZED CONTROLLED TRIAL ASSESSING THE IMPACT OF EARLY DORSAL VENOUS COMPLEX (eDVC) LIGATION ON URINARY CONTINENCE RECOVERY AFTER ROBOT-ASSISTED RADICAL PROSTATECTOMY. <i>Journal of Urology</i> , 2021, 206, .	0.2	0
81	MP45-02â€¦EXTERNAL VALIDATION AND HEAD-TO-HEAD COMPARISON OF ALL THE PROGNOSTIC MODELS RECOMMENDED BY THE EUROPEAN ASSOCIATION OF UROLOGY GUIDELINES TO PREDICT ONCOLOGIC OUTCOMES IN PATIENTS WITH RENAL CELL CARCINOMA. <i>Journal of Urology</i> , 2021, 206, .	0.2	0
82	MP48-19â€¦STAGE AND CANCER SPECIFIC MORTALITY DIFFERS WITHIN SPECIFIC ASIAN ETHNIC GROUPS IN UPPER TRACT UROTHELIAL CARCINOMA. <i>Journal of Urology</i> , 2021, 206, .	0.2	0
83	MP64-05â€¦A NEW MODEL FOR PREDICTION OF HIGH-RISK FEATURES AMONG UNFAVORABLE INTERMEDIATE RISK PROSTATE CANCER PATIENTS. <i>Journal of Urology</i> , 2021, 206, .	0.2	0
84	MP30-03â€¦POSITIVE PREDICTIVE VALUE OF MPMRI IN MEN UNDER ACTIVE SURVEILLANCE: CAN THE BIOPSY HISTORY INFLUENCE RADIOLOGICAL ASSESSMENT?. <i>Journal of Urology</i> , 2021, 206, .	0.2	0
85	The detection of a PI-RADS 4â€¦5 lesion at multiparametric MRI before confirmatory biopsy is the strongest predictor of disease progression among men with low-risk prostate cancer included in an active surveillance prospective protocol. <i>European Urology Open Science</i> , 2021, 32, S132.	0.2	0
86	External validation and head-to-head comparison of all the prognostic models recommended by the european association of urology guidelines to predict oncologic outcomes in patients with renal cell carcinoma. <i>European Urology Open Science</i> , 2021, 32, S150.	0.2	0
87	The Effect of 10 Most Common Nonurological Primary Cancers on Survival in Men With Secondary Prostate Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 754996.	1.3	0
88	Final results of a prospective, randomized controlled trial assessing the impact of early dorsal venous complex (EDVC) ligation on urinary continence recovery after robot-assisted radical prostatectomy. <i>European Urology Open Science</i> , 2021, 32, S3.	0.2	0
89	MP53-01â€¦DETECTION OF CLINICALLY SIGNIFICANT PROSTATE CANCER IN MPMRI VISIBLE LESIONS: SIZE MATTERS. RESULTS FROM A LARGE, TWO-INSTITUTIONAL SERIES. <i>Journal of Urology</i> , 2022, 207, .	0.2	0
90	MP47-09â€¦THE ADDED VALUE OF HISTOLOGICAL SUBTYPE IN THE PREDICTION OF ONCOLOGIC OUTCOMES IN PATIENTS WITH NON-METASTATIC PAPILLARY RENAL CELL CARCINOMA. <i>Journal of Urology</i> , 2022, 207, .	0.2	0

#	ARTICLE	IF	CITATIONS
91	MP48-13â€fTHE KEY ROLE OF CONCOMITANT ANDROGEN-DEPRIVATION THERAPY ON THE EFFICACY OF IMAGING GUIDED TREATMENTS IN MEN WITH BIOCHEMICAL RECURRENT PROSTATE CANCER AFTER RADICAL PROSTATECTOMY AND POSITIVE 68GA-PSMA PET/CT SCAN. Journal of Urology, 2022, 207, .	0.2	0
92	MP56-04â€fTHE ROLE OF FDG PET IN THE STAGING OF BLADDER CANCER PATIENTS CANDIDATE FOR RADICAL CYSTECTOMY. Journal of Urology, 2022, 207, .	0.2	0
93	PD59-07â€fNEGLECTED LYMPH NODAL METASTASES IN PATIENTS WITH RENAL CANCER: WHEN TO EXTEND THE ANATOMICAL TEMPLATE OF LYMPH NODE DISSECTION DURING NEPHRECTOMY. Journal of Urology, 2022, 207, .	0.2	0
94	PD17-03â€fCOMPARATIVE ANALYSES OF MICRO-ULTRASOUND VERSUS MRI-TARGETED BIOPSY FOR THE DIAGNOSIS OF CLINICALLY SIGNIFICANT PROSTATE CANCER. PRELIMINARY RESULTS FROM THE PROSPECTIVE US-MIRROR TRIAL. Journal of Urology, 2022, 207, .	0.2	0
95	PD15-08â€fWHEN TO DE-INTENSIFY ONCOLOGIC SURVEILLANCE SCHEME FOR NON-CLEAR CELL RENAL CELL CARCINOMA. Journal of Urology, 2022, 207, .	0.2	0
96	MP51-14â€fIMPACT OF 68GA-PSMA PET/CT AND METASTASIS-DIRECTED THERAPY ON CLINICAL RECURRENCE IN PATIENTS WITH BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY. RESULTS FROM A SINGLE CENTER SERIES. Journal of Urology, 2022, 207, .	0.2	0
97	MP48-12â€fOPTIMIZING TIMING AND INDICATIONS FOR 68GA-PSMA PET/CT IN PATIENTS WITH BIOCHEMICAL RECURRENT PROSTATE CANCER AFTER RADICAL PROSTATECTOMY. Journal of Urology, 2022, 207, .	0.2	0
98	PD60-11â€fIMPACT OF THE TIME ELAPSED BETWEEN PROSTATE BIOPSY AND SURGERY ON THE ACCURACY OF THE BRIGANTI NOMOGRAM PREDICTING LYMPH NODE INVASION IN MEN WITH CLINICALLY LOCALIZED PROSTATE CANCER. Journal of Urology, 2022, 207, .	0.2	0
99	PD35-02â€fWHEN IS NEOADJUVANT ANDROGEN DEPRIVATION THERAPY BENEFICIAL FOR HIGHLY AGGRESSIVE PROSTATE CANCER CANDIDATES TO RADICAL PROSTATECTOMY? IMPLICATIONS FOR MULTI-MODAL TAILORED APPROACHES AND TRIALS DESIGN. Journal of Urology, 2022, 207, .	0.2	0
100	PD60-03â€fTHE IMPACT OF HISTOLOGICAL VARIANTS ON THE PERFORMANCE CHARACTERISTICS OF 68GA-PSMA PET/CT IN THE PRIMARY AND RECURRENT SETTING. Journal of Urology, 2022, 207, .	0.2	0
101	MP51-08â€fDOES A POSITIVE MULTI-PARAMETRIC MRI ALWAYS WARRANT PROSTATE BIOPSY? THE IMPORTANCE OF INTEGRATING CLINICAL AND IMAGING DATA BASED ON A LARGE, MULTI-INSTITUTIONAL SERIES. Journal of Urology, 2022, 207, .	0.2	0
102	PD56-02â€fTHE DETRIMENTAL EFFECT OF FRAILTY STATUS ON RENAL FUNCTION RECOVERY AFTER PARTIAL NEPHRECTOMY â€“ LONG-TERM RESULTS FROM A PROSPECTIVE SURGICAL COHORT. Journal of Urology, 2022, 207, .	0.2	0
103	MP51-11â€fHAS THE INTRODUCTION OF MPMRI IN THE DIAGNOSTIC PATHWAY OF PROSTATE CANCER LED TO IMPROVED ONCOLOGICAL OUTCOMES AFTER RADICAL PROSTATECTOMY? RESULT FROM A LARGE SINGLE-INSTITUTIONAL SERIES. Journal of Urology, 2022, 207, .	0.2	0
104	MP12-07â€fTHE ANATOMICAL LOCATION OF LYMPHADENOPATHIES AT IMAGING PREDICTS THE RISK OF LYMPH NODE INVASION AT FINAL PATHOLOGY IN PATIENTS WITH RENAL CELL CARCINOMA. Journal of Urology, 2022, 207, .	0.2	0
105	MP23-09â€fACUTE KIDNEY INJURY AND ITS DURATION IN PATIENTS TREATED WITH RADICAL CYSTECTOMY IN THE ENHANCED RECOVERY AFTER SURGERY ERA: OPTIMIZING THE SELECTION OF PATIENTS FOR RESTRICTIVE FLUID THERAPY. Journal of Urology, 2022, 207, .	0.2	0
106	MP27-02â€fNOT ALL ADVERSE PATHOLOGY FEATURES ARE EQUAL: IDENTIFYING OPTIMAL CANDIDATES FOR ADJUVANT RADIOTHERAPY AMONG PATIENTS WITH ADVERSE PATHOLOGY AT RADICAL PROSTATECTOMY. Journal of Urology, 2022, 207, .	0.2	0
107	MP45-13â€fASSOCIATION BETWEEN POLYMORPHISMS OF HOMOLOGOUS RECOMBINATION RAD51B AND DISEASE RECURRENCE IN A PROSPECTIVE COHORT OF PROSTATE CANCER PATIENTS UNDERGOING RADICAL PROSTATECTOMY. Journal of Urology, 2022, 207, .	0.2	0
108	MP15-19â€fCAN LOW RISK DISEASE OUTSIDE THE INDEX LESION BE LEFT UNTREATED IN MEN SUITABLE FOR FOCAL THERAPY? DEVELOPMENT OF NOVEL CRITERIA TO IDENTIFY POTENTIAL CANDIDATES FOR FOCAL THERAPY AMONG PATIENTS WITH INTERMEDIATE RISK PROSTATE CANCER AND POSITIVE MULTI-PARAMETRIC MRI. Journal of Urology, 2022, 207, .	0.2	0

#	ARTICLE	IF	CITATIONS
109	MP43-19â€fDROP-OUT RATES FROM ACTIVE SURVEILLANCE FOR DISEASE PROGRESSION REMAIN CONSISTENT AND NOT NEGLIGIBLE OVER TIME. A PLEA FOR LONG-TERM ASSESSMENT BASED ON A LARGE, PROSPECTIVELY COLLECTED ACTIVE SURVEILLANCE COHORT. <i>Journal of Urology</i> , 2022, 207, .	0.2	0
110	MP27-03â€fDELAYING POST-OPERATIVE RADIATION THERAPY AFTER RADICAL PROSTATECTOMY IS ASSOCIATED WITH INCREASED FUNCTIONAL OUTCOMES: RESULTS FROM A LARGE SINGLE, REFERRAL CENTER SERIES. <i>Journal of Urology</i> , 2022, 207, .	0.2	0
111	PD42-03â€fONCOLOGIC SURVEILLANCE INTENSITY FOR VARIANT HISTOLOGY VERSUS PURE UROTHELIAL CARCINOMA OF THE BLADDER AFTER RADICAL CYSTECTOMY. <i>Journal of Urology</i> , 2022, 207, .	0.2	0
112	MP50-09â€fIMAGING INTENSITY AFTER SURGERY FOR CLEAR CELL RENAL CELL CARCINOMA. <i>Journal of Urology</i> , 2022, 207, .	0.2	0
113	MP56-02â€fNEOADJUVANT PEMBROLIZUMAB MAY RESULT IN LONG-TERM OUTCOME IMPROVEMENT IN BIOMARKER-UNSELECTED PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER (MIBC): UPDATED RESULTS FROM PURE-01. <i>Journal of Urology</i> , 2022, 207, .	0.2	0
114	PD58-10â€fIMPLEMENTING THE FOLLOW-UP SCHEDULE AFTER RADICAL NEPHROURETRECTOMY FOR LOW RISK UPPER TRACT UROTHELIAL CARCINOMA. <i>Journal of Urology</i> , 2022, 207, .	0.2	0